Results 71 to 80 of about 2,862,477 (306)

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

open access: yesFEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani   +6 more
wiley   +1 more source

Interleukin-6 levels in the control and AAA groups.

open access: yes, 2023
There was no significant difference in plasma levels of IL-6 between groups (P = .17). AAA, abdominal aortic aneurysm; IL-6, interleukin-6.
Lenka Maliskova (8781746)   +14 more
core   +1 more source

Perspectives on the Genetic Associations of Ankylosing Spondylitis

open access: yesFrontiers in Immunology, 2021
Ankylosing spondylitis (AS) is a common form of inflammatory spinal arthritis with a complex polygenic aetiology. Genome-wide association studies have identified more than 100 loci, including some involved in antigen presentation (HLA-B27, ERAP1, and ...
B. Paul Wordsworth   +6 more
doaj   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

open access: yesFEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová   +2 more
wiley   +1 more source

Validation of an automated enzyme immunoassay for interleukin-6 for routine clinical use [PDF]

open access: yes, 1998
Serum levels of Interleukin-6 (IL-6), a proinflammatory cytokine, are increased in early stages of inflammatory diseases such as infection and sepsis. Assay systems which permit its measurement within a few hours and as a single measurement have not been
Peter Fraunberger   +17 more
core   +1 more source

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection

open access: yesFEBS Open Bio, EarlyView.
The dual roles of CC and CXC chemokines in distinguishing active, latent, and subclinical tuberculosis were reviewed, along with an evaluation of their potential as diagnostic biomarkers and therapeutic targets to advance precision medicine in tuberculosis management. The graphical abstract was generated with AI assistance (Gemini 3.0).
Xuying Yin, Dangsheng Xiao, Jiezuan Yang
wiley   +1 more source

Molecular characterization of covRS mutations in M1UK Streptococcus pyogenes

open access: yesFEBS Open Bio, EarlyView.
Group A Streptococcus (GAS) acquires covRS mutations driving a hypervirulent bacterial state, frequently associated with invasive disease‐like necrotizing fasciitis. We demonstrate that the newly emerged M1UK GAS lineage can also acquire these mutations.
Jarrad Pritchard   +12 more
wiley   +1 more source

Evaluating the involvement of autolysosomes in the nuclear translocation of fluorescent proteins

open access: yesFEBS Open Bio, EarlyView.
Endogenously expressed fluorescent proteins can be degraded by autophagy and transported to cell nuclei via the nuclear pore complex. But in some cell lines, for example, HeLa cells which are positive for immunoreactivity of a receptor ligand, such as UCN I, in cell nuclei, fusion of autolysosome with the nuclear envelope is involved in the nuclear ...
Keiichi Ikeda
wiley   +1 more source

Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding [PDF]

open access: yes, 2009
Background: Atherosclerosis is an inflammatory process that develops in individuals with known risk factors that include hypertension and hyperlipidaemia, influenced by diet.
Dower, S.   +25 more
core   +1 more source

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

open access: yesDrug Design, Development and Therapy, 2018
Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M Health Science Center College of Medicine, Bryan, TX, USA Abstract: Risankizumab, a ...
Haugh IM   +3 more
doaj  

Home - About - Disclaimer - Privacy